These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34408797)

  • 1. Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma.
    Yassaie O; Chehroudi C; Black PC
    Ther Adv Med Oncol; 2021; 13():17588359211039052. PubMed ID: 34408797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer.
    Suh J; Yoo S
    Transl Cancer Res; 2020 Oct; 9(10):6537-6545. PubMed ID: 35117263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
    Kim HS; Seo HK
    Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
    Steinberg RL; Thomas LJ; Nepple KG
    Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
    Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
    BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Kokorovic A; Ory J; Saad F
    Curr Opin Support Palliat Care; 2022 Mar; 16(1):48-53. PubMed ID: 35086977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward.
    Chehroudi AC; Black PC
    Can Urol Assoc J; 2020 Jun; 14(6):204-213. PubMed ID: 31977307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of intravesical BCG in urothelial carcinoma of the bladder.
    Alhunaidi O; Zlotta AR
    Ecancermedicalscience; 2019; 13():905. PubMed ID: 30915163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.
    Syed S; Rahman M; Israr A; Anwar M; Khatroth S; Safi D; Kamran A
    SAGE Open Med; 2023; 11():20503121231160408. PubMed ID: 36949824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.
    Audisio A; Buttigliero C; Delcuratolo MD; Parlagreco E; Audisio M; Ungaro A; Di Stefano RF; Di Prima L; Turco F; Tucci M
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
    Basile G; Pederzoli F; Bandini M; Raggi D; Gallina A; Salonia A; Briganti A; Montorsi F; Spiess PE; Necchi A
    Urol Oncol; 2021 Oct; 39(10):631-641. PubMed ID: 33766463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
    Tse J; Singla N; Ghandour R; Lotan Y; Margulis V
    Expert Opin Investig Drugs; 2019 Sep; 28(9):757-770. PubMed ID: 31412742
    [No Abstract]   [Full Text] [Related]  

  • 20. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.